Key facts
- Biogen and UCB's dapirolizumab pegol met its primary endpoint in a Phase 3 trial.
- The drug is for patients with systemic lupus erythematosus (lupus).
- The trial demonstrated efficacy of the drug.
Systemic lupus erythematosus (SLE), commonly known as lupus, is a chronic autoimmune disease that can affect various parts of the body, including joints, skin, kidneys, blood cells, brain, heart, and lungs. Developing effective treatments for lupus is a significant area of focus in the pharmaceutical industry due to the disease's complexity and impact on patients' lives.